Navigation Links
PPCE Announces Strategic Partnership With ECLINSO AG
Date:9/13/2012

PUNE, India, Sept. 13, 2012 /PRNewswire-iReach/ -- PPCE, a high-quality Clinical Data Management services company providing CDISC-certified services announced today that it has entered into a strategic partnership agreement with ECLINSO AG, a leading provider of eClinical information technology, consulting and business process outsourcing services.

PPCE Data Management Services and ECLINSO's Trialforce Platform offer unparalleled flexibility and adaptability to both Sponsors and Clinical Research Organizations (CROs) for capturing and managing their clinical data.

With extensive experience in serving pharmaceutical and biotechnology companies of all sizes, PPCE, a company based in Pune, India has selected ECLINSO's Trialforce platform to enable it to offer high-quality eClinical application services and optimized data management services to their clients.

Trialforce a single, unified application platform is a comprehensive, on demand, SaaS based solution for conducting Clinical Trials. It offers enterprise class software for Electronic Data Capture (EDC), Electronic Source Record (ESR), eTMF aligned Document Management (DMS), Diagnostic imaging, and Regulatory Solutions (eCTD).

ECLINSO's strong foundation of managed IT services, dedicated on demand servers and global 24/7 support, offers Sponsors and Clinical Research Organizations CDISC compliant solutions designed to accelerate clinical development.

"PPCE is delighted to have reached this partnership agreement with ECLINSO, enabling us to offer enterprise class eClinical solutions and services.

ECLINSO's Trialforce platform accelerates the whole clinical trial process and thus saves time and money which will enable PPCE to efficiently continue providing its clients with the high-quality eClinical solutions and services they have come to expect. Our combined experience and resources will significantly improve clinical trial efficiency while reducing costs for our clients," stated Firdaus Dastoor, Chairman PPCE.

"PPCE's strong presence with global organizations and proven established execution capability throughout Asia will enable ECLINSO to fulfill increasing customer demand for its Trialforce platform," said Frank Pijpers, CEO ECLINSO.

About ECLINSO (www.eclinso.com)

ECLINSO is an innovative provider of Clinical Technology solutions and global support services to enhance the conduct of clinical trials. Our international reputation combined with our deep industry understanding and innovative approach through Trialforce is setting the benchmark for the use of 'on demand' solutions for clinical trials. Through Trialforce we deliver an innovative standards, affordable, scalable and easy-to-use platform that enables sponsors and CRO's to rapidly deploy an integrated EDC/Data Management/eClinical suite. The solution is based on an uncomplicated SaaS pricing model, that offers minimal upfront costs and significantly lower initial licensing fees compared to those fees traditionally associated with the use of EDC solutions.

ECLINSO was formed in 1995 and has offices in Basel, Switzerland, New Jersey and California, USA.

About PPCE (www.ppceworld.com)

Established in 1997, PPCE offers cost effective clinical data management and bio-statistical services for paper based, electronic and hybrid studies.  Solutions used are validated, world renowned and regulatory compliant across the globe.  Fully validated, 21 CFR Part 11 compliant platforms like Oracle Clinical and Trialforce enable PPCE to offer its clients world class tools for high quality data.

We are a company focused on quality and on-time delivery for our clients.  PPCE's sixteen years of experience certifying companies for quality management means that critical aspects of quality, such as integrity of data, confidentiality and customer orientation, form part of the organizational culture.  As a result of this culture we enjoy a high level of customer satisfaction and long term relationships with our clients.

Contact:
Jaya Kumawat
Head-Biometrics, PPCE
+ 91 20 2674 5024

Media Contact: George Masoura ECLINSO, 855 245 0987, george.masoura@eclinso.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE ECLINSO
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendia Announces Five Studies in Breast Cancer for Presentation at the American Society of Clinical Oncology 2012 Breast Cancer Symposium
2. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
3. Soligenix Announces Issuance of US Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
4. Henry Schein Announces New $500 Million Credit Facility
5. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
6. Biodel Announces Phase 2 Clinical Trial Initiation Of Ultra-Rapid-Acting Insulin Candidate BIOD-123
7. Simcere Pharmaceutical Group Announces Appointment of New Chief Executive Officer
8. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
9. Elbit Imaging Ltd. Announces Standard & Poors Maalot Changes Rating of Companys Notes
10. 3SBio Inc. Announces Receipt of "Going Private" Proposal at $15 Per ADS
11. IncellDx, Inc. Announces an Agreement with BioReference Laboratories, Inc. to Conduct a 10,000 Sample Study Using a Slideless Pap Smear
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... 2016 , ... Research has shown that building shame resilience ... and level of relapse. , At the 2016 iaedp Symposium, the ... the critical tasks of the recovery phase and beyond including relapse prevention and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
(Date:2/5/2016)... City, UT (PRWEB) , ... February 05, 2016 , ... ... Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist in ... Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV show, ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
Breaking Medicine News(10 mins):